EMA Withdrawn: Pemetrexed Krka (pemetrexed disodium) — KRKA d.d.

View source ↗

Summary

EMA has withdrawn the product Pemetrexed Krka (pemetrexed disodium) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed Krka (pemetrexed disodium)

Snippet

Status: Withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung;Mesothelioma. MAH: KRKA d.d.. Decision date: 15/02/2023